Table 2.

Pharmacogenetic polymorphism analysis in patients surviving >15 months

GenePolymorphismsP
ABCB1 3435C/C, 4/10 (40%)C/T, 7/29 (24%)T/T, 6/12 (50%)0.24
ABCG2 421C/C, 12/44 (27%)C/A, 4/6 (67%)A/A, 0/0 (0%)0.05
CYP3A4*1BA/A, 16/43 (37%)A/G, 0/5 (0%)G/G, 1/2 (50%)0.10
CYP3A5*3CA/A, 1/2 (50%)A/G, 0/5 (0%)G/G, 16/440.10
MAP4 68G/G, 14/46 (30%)G/A, 3/5 (60%)A/A, 0/0 (0%)0.18
MAP4 1280C/C, 7/25 (28%)C/A, 5/18 (28%)A/A, 3/5 (60%)0.37
MAPT-13G/G, 0/3 (0%)G/A, 7/18 (39%)A/A, 10/29 (34%)0.26
MAPT 3674A/A, 10/30 (33%)G/A, 6/17 (35%)G/G, 0/3 (0%)0.29